Inspire Medical Systems, Inc. INSP
We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). 10-K, Item 1
- Employees
- 1,333
- Headquarters
- Golden Valley, MN
- CEO
- Timothy P. Herbert
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $912.0M through the costs to a net profit of $145.4M · income statement of the 10-K
INSP among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
29 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 13, 2026 against Feb 10, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
3facts worth reading about the other 8 checks found nothing to note
-
Receivables growing faster than revenueReceivables +28.6% ($93.1M to $119.7M) vs revenue +13.6% ($802.8M to $912.0M), +15.0 pts apart
-
Cash from operations lower than net incomeCash from operations $117.0M vs net income $145.4M (FY ending Dec 31, 2025)
-
Inventory growing faster than revenueInventory +81.3% ($80.1M to $145.3M) vs revenue +13.6% ($802.8M to $912.0M), +67.7 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Reserves for excess and obsolete inventory
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
29 paragraphs in Risk Factors that were not in the 10-K filed Feb 10, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6, 2025, the City of Pontiac…
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
In addition, we are currently a party to multiple adversarial proceedings with Nyxoah regarding our patent portfolio and the patents of third parties. For additional information, see Note 11, Commitments and Contingencies to the
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
In the course of conducting our business, we must adequately address quality issues that may arise with our Inspire system, including defects in third-party components included in our Inspire system. There can be no
-
Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
We rely extensively on information technology systems to conduct our business and collect, store, process and transmit confidential and sensitive information, including personal information of (or relating to) customers, patients and our employees and contractors. These systems support, among other things, manufacturing and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $407.9M | $624.8M | $802.8M | $912.0M |
| Net income | −$44.9M | −$21.2M | $53.5M | $145.4M |
| Operating cash flow | $11.6M | $24.7M | $130.2M | $117.0M |
| Free cash flow | $2.5M | $1.0M | $91.1M | $78.5M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$912.0M ▲ 13.6% in FY2025$145.4M ▲ 171.8% in FY2025$78.5M ▼ 13.9% in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 2, 2026Quarterly results, Regulation FD disclosure 8-K items 2.02, 7.01
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Inspire Medical Systems, Inc., Golden Valley, MN · from the 10-K filed Feb 13, 2026
We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway.
- Headquarters
- Golden Valley, MN
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 1,333 employees, of which 1,243 are in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 13, 2026 (open at SEC), compared with the 10-K filed Feb 10, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.